Linagliptin

• Description :

  Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM.

• Product Name Alternative :

  BI 1356

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H335

• Target :

  Autophagy; Dipeptidyl Peptidase; Ferroptosis

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Autophagy; Metabolic Enzyme/Protease

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/Linagliptin.html

• Purity :

  99.91

• Solubility :

  DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C1N(C2=C(C(N1CC3=NC(C)=C4C=CC=CC4=N3)=O)N(CC#CC)C(N5CCC[C@@H](N)C5)=N2)C

• Molecular Formula :

  C25H28N8O2

• Molecular Weight :

  472.54

• Precautions :

  H315, H319, H335

• References & Citations :

  [1]Eckhardt M, et al. 8- (3- (R) -aminopiperidin-1-yl) -7-but-2-ynyl-3-methyl-1- (4-methyl-quinazolin-2-ylmethyl) -3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 d|[2]Thomas L, et al. (R) -8- (3-amino-piperidin-1-yl) -7-but-2-ynyl-3-methyl-1- (4-methyl-quinazolin-2-ylmethyl) -3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action|[3]Schurmann C, et al. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice. J Pharmacol Exp Ther. 2012 Jul;342 (1) :71-80.|[4]Huan Y, et al. The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo. Sci Rep. 2017 Jun 28;7 (1) :4351.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  DPP-4

• CAS Number :

  [668270-12-0]